This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
3-MeO-PCP: Difference between revisions
>Graham wiki ref formatting |
>Larnaca |
||
| (7 intermediate revisions by 5 users not shown) | |||
| Line 6: | Line 6: | ||
'''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to substances like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking [[NMDA receptor|NMDA receptors]] in the brain. | '''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to substances like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking [[NMDA receptor|NMDA receptors]] in the brain. | ||
3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="Morris2014">{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE | volume=6 | issue=7–8 | pages=614–632 | date= July 2014 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1620 | issn=19427603 | doi=10.1002/dta.1620}}</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the [[research chemicals]] market.<ref name="Morris2014"/> | 3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="Morris2014">{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE | volume=6 | issue=7–8 | pages=614–632 | date= July 2014 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1620 | issn=19427603 | doi=10.1002/dta.1620}}</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the [[research chemicals]] market.<ref name="Morris2014" /> | ||
Like other arylcyclohexylamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]]. | Like other arylcyclohexylamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]]. | ||
| Line 186: | Line 186: | ||
*'''United States:''' 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP. | *'''United States:''' 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP. | ||
*'''Czech Republic''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation | vauthors=(([email protected], A. C.-)) | title=463/2013 Sb. Nařízení vlády o seznamech návykových látek | url=https://www.zakonyprolidi.cz/cs/2013-463}}</ref> | *'''Czech Republic''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation | vauthors=(([email protected], A. C.-)) | title=463/2013 Sb. Nařízení vlády o seznamech návykových látek | url=https://www.zakonyprolidi.cz/cs/2013-463}}</ref> | ||
*'''The Netherlands''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation| title=Opiumwet, Lijst I, (Dutch) | year=2023 | url=https://wetten.overheid.nl/BWBR0001941/2023-09-12#BijlageI}}</ref> | |||
*'''Italy:''' 3-MeO-PCP is a Schedule I controlled substance.<ref>https://www.gazzettaufficiale.it/atto/vediMenuHTML?atto.dataPubblicazioneGazzetta=2021-10-18&atto.codiceRedazionale=21A06118&tipoSerie=serie_generale&tipoVigenza=originario</ref> | |||
==See also== | ==See also== | ||
| Line 215: | Line 217: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Psychoactive substance]] | |||
[[Category:Arylcyclohexylamine]] | [[Category:Arylcyclohexylamine]] | ||
[[Category:Piperidine]] | [[Category:Piperidine]] | ||